Vps8 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VPS8 (vacuolar protein sorting 8 homolog) encodes a CORVET-specific tethering subunit that organizes early-to-late endosomal maturation steps. Unlike HOPS-enriched components that dominate terminal lysosome fusion, VPS8 is most strongly linked to CORVET biology and Rab5-positive endosomal handling.[1][2] This distinction matters mechanistically: VPS8-centered defects are expected to disrupt upstream endosomal sorting and cargo progression before the final degradative stage.
In neurodegeneration research, VPS8 is relevant as a systems-level node in endolysosomal integrity. Even when VPS8 is not a primary disease driver, altered CORVET function can exacerbate trafficking delay, inflammatory signaling, and proteostasis burden in neurons and glia.[3][4]
| Property | Value |
|---|---|
| Gene Symbol | VPS8 |
| Full Name | Vacuolar Protein Sorting 8 Homolog |
| Chromosomal Location | 3q27.1 |
| NCBI Gene ID | 23355 |
| OMIM | 608554 |
| Ensembl ID | ENSG00000124104 |
| UniProt ID | Q9H5K3 |
| Core Complex Context | CORVET-associated endosomal tethering |
Experimental work indicates that VPS8 cooperates with Rab5-family machinery to localize CORVET on endosomal membranes and promote tethering events that precede productive fusion.[1:1][5] N-terminal VPS8 regions are especially important for proper complex localization and function.[2:1]
VPS8 helps enforce orderly cargo progression from early endosomes toward late endosome/lysosome pathways. Disrupting this step can cause cargo retention, altered receptor recycling, and reduced degradative throughput, all of which are highly relevant in post-mitotic neurons.[3:1][6]
CORVET and HOPS share a class C VPS core but differ in accessory subunits and subcellular preference. VPS8 abundance influences the CORVET/HOPS balance, and this balance modulates where tethering capacity is deployed along the endosomal axis.[6:1]
Direct human VPS8-neurodegeneration genetics remains limited compared with major disease genes such as GBA or LRRK2, but pathway-level evidence supports VPS8 relevance because endolysosomal impairment is a recurrent mechanism in Parkinson's disease, Alzheimer's disease, and related disorders.[3:2][4:1]
Inefficient endosomal progression can indirectly influence turnover of proteins central to neurodegenerative pathology, including SNCA, APP, and MAPT. The expected consequence is prolonged residence of misfolded or aggregation-prone cargo in stress-sensitive compartments.[3:3][7]
Human studies have linked VPS8 variation to severe multisystem developmental phenotypes in some families, reinforcing the concept that VPS8 dosage can be biologically consequential in vivo.[8] This evidence supports caution when interpreting even partial VPS8 dysfunction in neuronal models.
Useful readouts for VPS8-pathway dysfunction include:
These phenotypes can be integrated with transcriptomic and imaging assays to map where VPS8 perturbation sits in a disease cascade.[1:2][2:2]
Because VPS8 sits upstream in endosomal flow, therapeutic concepts typically focus on improving global traffic efficiency and lysosomal endpoint competence rather than targeting VPS8 alone. This includes interventions that support endolysosomal flux and reduce aggregate burden in vulnerable circuits.[3:4][9]
Current evidence does not yet support a VPS8-specific disease-modifying therapy for common neurodegenerative disorders. A pragmatic near-term strategy is biomarker-guided patient stratification by endolysosomal dysfunction signatures, then pathway-level intervention testing.[4:2][9:1]
The study of Vps8 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Balderhaar HJ, Lachmann J, Yavavli E, et al. The CORVET subunit Vps8 cooperates with the Rab5 homolog Vps21 to induce clustering of late endosomal compartments. Molecular Biology of the Cell. 2009. ↩︎ ↩︎ ↩︎
Plemel RL, Lobingier BT, Brett CL, et al. The N-terminal domains of Vps3 and Vps8 are critical for localization and function of the CORVET tethering complex on endosomes. PLOS ONE. 2013. ↩︎ ↩︎ ↩︎
Kaur G, Lakkaraju A. Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Current Opinion in Neurobiology. 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Mony VK, Benjamin S, O'Rourke EJ. Dysfunctional Autophagy and Endolysosomal System in Neurodegenerative Diseases: Relevance and Therapeutic Options. Frontiers in Cellular Neuroscience. 2020. ↩︎ ↩︎ ↩︎
Lachmann J, Ungermann C, Engelbrecht-Vandré S. Functional separation of endosomal fusion factors and the class C core vacuole/endosome tethering (CORVET) complex in endosome biogenesis. Journal of Biological Chemistry. 2013. ↩︎
van der Beek J, Jonker C, van der Welle R, Liv N, Klumperman J. CORVET-specific subunit levels determine the balance between HOPS/CORVET endosomal tethering complexes. Scientific Reports. 2024. ↩︎ ↩︎
Ando Y, Imamura S, Hong A, et al. Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎
Shamseldin HE, et al. Molecular etiology of arthrogryposis in multiple families of mostly Turkish origin. Journal of Clinical Investigation. 2016. ↩︎
Xiao H, Chen D, Fang Z, et al. Autophagy in Alzheimer's disease pathogenesis: Therapeutic potential and future perspectives. Ageing Research Reviews. 2021. ↩︎ ↩︎